529 related articles for article (PubMed ID: 28537449)
21. A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action.
Drab SR; Philis-Tsimikas A
Pharmacotherapy; 2014 Mar; 34(3):291-302. PubMed ID: 24132869
[TBL] [Abstract][Full Text] [Related]
22. Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.
Clements JN; Threatt T; Ward E; Shealy KM
Clin Pharmacokinet; 2017 May; 56(5):449-458. PubMed ID: 27699623
[TBL] [Abstract][Full Text] [Related]
23. Flexibly timed once-daily dosing with degludec: a new ultra-long-acting basal insulin.
Josse RG; Woo V
Diabetes Obes Metab; 2013 Dec; 15(12):1077-84. PubMed ID: 23577589
[TBL] [Abstract][Full Text] [Related]
24. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
Owens DR; Bolli GB
Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
[TBL] [Abstract][Full Text] [Related]
25. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
Shiramoto M; Eto T; Irie S; Fukuzaki A; Teichert L; Tillner J; Takahashi Y; Koyama M; Dahmen R; Heise T; Becker RH
Diabetes Obes Metab; 2015 Mar; 17(3):254-60. PubMed ID: 25425297
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG
Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412
[TBL] [Abstract][Full Text] [Related]
27. Clinical use of the co-formulation of insulin degludec and insulin aspart.
Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
[TBL] [Abstract][Full Text] [Related]
28. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
[TBL] [Abstract][Full Text] [Related]
29. Will the next generation of basal insulins offer clinical advantages?
Garber AJ
Diabetes Obes Metab; 2014 Jun; 16(6):483-91. PubMed ID: 24118819
[TBL] [Abstract][Full Text] [Related]
30. Basal insulins: Pharmacological properties and patient perspectives.
Abrahamson MJ
Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
[TBL] [Abstract][Full Text] [Related]
31. Review of the Next Generation of Long-Acting Basal Insulins: Insulin Degludec and Insulin Glargine.
Stailey M; Conway SE
Consult Pharm; 2017 Jan; 32(1):42-46. PubMed ID: 28077204
[TBL] [Abstract][Full Text] [Related]
32. New Insulins and New Aspects in Insulin Delivery.
Woo VC
Can J Diabetes; 2015 Aug; 39(4):335-43. PubMed ID: 26233724
[TBL] [Abstract][Full Text] [Related]
33. Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.
Fadini GP; Feher M; Hansen TK; de Valk HW; Koefoed MM; Wolden M; Zimmermann E; Jendle J
J Clin Endocrinol Metab; 2019 Dec; 104(12):5977-5990. PubMed ID: 31397845
[TBL] [Abstract][Full Text] [Related]
34. Hypoglycemia rates with basal insulin analogs.
Little S; Shaw J; Home P
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
[TBL] [Abstract][Full Text] [Related]
35. Insulin degludec: a novel basal insulin analogue.
Goldman-Levine JD; Patel DK; Schnee DM
Ann Pharmacother; 2013 Feb; 47(2):269-77. PubMed ID: 23386075
[TBL] [Abstract][Full Text] [Related]
36. Basal weekly insulins: the way of the future!
Rosenstock J; Del Prato S
Metabolism; 2022 Jan; 126():154924. PubMed ID: 34728221
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
Hompesch M; Morrow L; Watkins E; Roepstorff C; Thomsen HF; Haahr H
Clin Ther; 2014 Apr; 36(4):507-15. PubMed ID: 24508419
[TBL] [Abstract][Full Text] [Related]
38. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
Pollock RF; Tikkanen CK
J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
[TBL] [Abstract][Full Text] [Related]
39. The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa.
Rosenstock J; Juneja R; Beals JM; Moyers JS; Ilag L; McCrimmon RJ
Endocr Rev; 2024 May; 45(3):379-413. PubMed ID: 38224978
[TBL] [Abstract][Full Text] [Related]
40. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
